Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand · Tablet · Updated Nov 11, 2026

Savaysa 60 mg tablet price what pharmacies pay, and what you should

Pharmacies pay$465.35for 30 tablets · $15.51 per tablet
Fair cash price$545.65cost + 15% + $10.50 fee
No change in 4 weeks+6.0% in a yearLast change Jul 1, 2026: WAC Adjustment

Is my price fair?

Check the price you were quoted

Type what the pharmacy asked for savaysa 60 mg tablet and see the markup over what they pay.

How many?
$
Pharmacies payNADAC this week$465.35
Online cost-pluscost + 15% + fees$545.15
Fair cash pricecost + 15% + $10.50 fee$545.65
Your quotetype it above-
Pharmacies pay about $465.35 for 30 tablets. A fair cash price is around $545.65. Type your quote to see your markup.

A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.

Savaysa 60 mg price history

What pharmacies pay for 30 tablets, weekly
$435.28$446.53$457.79$469.04DecFebAprJunAugOct
What pharmacies paid for 30 tablets of savaysa 60 mg tablet over 52 weeks: from $439.01 on Nov 12, 2025 to $465.35 on Nov 11, 2026.
Now
$465.35
52-week low
$438.97
52-week high
$465.35
A year ago
$439.01

Why the price changed

EffectiveBeforeAfterChangeReason
Jul 1, 2026$14.63$15.51+6.0%WAC Adjustment
May 20, 2026$14.63$14.63No changepharmacies' invoice prices changed (survey)
Apr 22, 2026$14.66$14.63-0.2%pharmacies' invoice prices changed (survey)
Mar 18, 2026$14.68$14.66-0.1%pharmacies' invoice prices changed (survey)
Feb 18, 2026$14.66$14.68+0.1%pharmacies' invoice prices changed (survey)
Jan 21, 2026$14.67$14.66-0.1%pharmacies' invoice prices changed (survey)
Dec 17, 2025$14.68$14.67No changepharmacies' invoice prices changed (survey)
Nov 19, 2025$14.63$14.68+0.3%pharmacies' invoice prices changed (survey)

Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.

What did you pay for savaysa 60 mg tablet? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recallsNone on record

Every manufacturer and package code

1 company sell savaysa 60 mg tablet under 1 package code (NDC).

MakerPack sizesPackage codesPer unit
Daiichi Sankyo Inc.30 tablets65597-203-30 $15.51
All 1 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Questions to ask your pharmacist

  1. "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
  2. "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
  3. "Do you match other pharmacies or accept discount cards?" Many do, if you ask.

These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.

Other savaysa strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
30 mg tablet Brand$15.48$464.44 / 30 tabletsNo change+5.0%

Official label & what changed

Last changedJuly 14, 2025
Version28 of 20
EffectiveJul 10, 2025
Read the label

These highlights do not include all the information needed to use SAVAYSA safely and effectively. See full prescribing information for SAVAYSA. SAVAYSA® (edoxaban) tablets, for oral use Initial U.S. Approval: 2015

This drug has a boxed warning

WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA

WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA

See full prescribing information for complete boxed warning.

(A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used (5.1).

(B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS: Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance (2.4, 5.2, 14).

(C) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures (5.4).

A. REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN

SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used [see Dosage and Administration (2.1), Warnings and Precautions (5.1), and Clinical Studies (14.1)].

B. PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS

Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance [see Dosage and Administration (2.4), Warnings and Precautions (5.2), and Clinical Studies (14.1)].

C. SPINAL/EPIDURAL HEMATOMA

Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

use of indwelling epidural catheters

concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

a history of traumatic or repeated epidural or spinal punctures

a history of spinal deformity or spinal surgery

optimal timing between the administration of SAVAYSA and neuraxial procedures is not known

[see Warnings and Precautions (5.4)].

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.4)].

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions (5.4)].

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about savaysa 60 mg tablet

How much does savaysa 60 mg tablet cost without insurance?

Pharmacies pay about $465.35 for 30 tablets ($15.51 per tablet) as of November 11, 2026. A fair cash price is about $545.65: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $545.15 including shipping.

Is my price for savaysa 60 mg tablet fair?

Compare it with the fair cash price of $545.65 for 30 tablets. Up to about $682.06 is fair; above $1,091.30 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.

Is savaysa 60 mg tablet getting more expensive?

Over the last four weeks the price pharmacies pay held steady. Over a year it rose 6.0%. See the 52-week chart.

Who makes savaysa 60 mg tablet?

1 company: Daiichi Sankyo Inc.. See every package code.

Is savaysa in shortage?

No shortage is reported right now. We check every day.

Has savaysa been recalled?

No recalls are on record.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about savaysa 60 mg tablet

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.